Old wine in new pipes? Treatment of advanced non-small cell lung cancer with trofosfamide.
Onkologie
Department of Internal Medicine I, Pneumology and Allergology, Jena University Hospital, Friedrich-Schiller-University Jena, Germany.
Published: March 2014
Background: The aim of this retrospective study was to examine the effect of oral trofosfamide in patients with advanced non-small cell lung cancer (NSCLC).
Patients And Methods: Patients with histologically or cytologically proven NSCLC, who had received at least 2 other therapies, were enrolled. The primary clinical end point was progression-free survival (PFS); secondary end points included overall survival (OS), response rate and toxicity.
Results: 23 patients were enrolled, 1 of whom was excluded due to non-compliance. The patients had received a median of 3 prior therapies (range 2-4). Regarding all 22 patients, median PFS was 14 weeks (95% confidence interval (CI) 9.96-18.04). The median OS was 32 weeks (95% CI 17.12-46.88). The median duration of trofosfamide therapy was 10.5 weeks (interquartile range 6.5-17.3). 20 patients (90.9%) had stable disease; 2 were not assessable. Trofosfamide therapy was stopped in 4 patients (18.2%) due to side effects.
Conclusion: Trofosfamide is an orally applicable, well-tolerated and cost-effective drug that works in patients with advanced NSCLC, who have undergone at least 2 lines of therapy. Trofosfamide seems to be a therapeutic option in NSCLC as a further therapy line. These preliminary data need to be confirmed in a larger trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000353544 | DOI Listing |
Similar Publications
OncoFlow: A Multiplexed Microfluidic Platform for Personalized Drug Sensitivity Assessment.
N Biotechnol
March 2025
The Mina & Everard Goodman Faculty of Life Sciences and the Institute for Nanotechnology and Advanced Materials, Bar Ilan University, Ramat-Gan, Israel. Electronic address:
While biomarker-guided treatments and NGS-based approaches are refining precision medicine, they are not universally applicable. The gap between the genomic characterization of tumors and their functional behavior is becoming increasingly evident. There is an escalating demand for functional assays that can customize cancer treatments for individual patients and bridge this gap.
View Article and Find Full Text PDFDosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity-Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. Electronic address:
Purpose/objective(s): Use of intensity-modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity.
Materials/methods: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n=313) or IMRT (n=1433) and were enrolled in the [quality consortium] prospective, multicenter statewide initiative.
Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review.
Front Oncol
February 2025
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Anaplastic lymphoma kinase (ALK) inhibitors have shown efficacy in treating ALK-positive advanced non-small cell lung cancer (NSCLC) patients. However, the effectiveness of ensartinib neoadjuvant therapy remains ambiguous. Herein, we reported that preoperative systemic treatment with the ALK inhibitor ensartinib can be beneficial for treating initially inoperable tumors.
View Article and Find Full Text PDFAn Exceptional Case of Garcin Syndrome Mimicking Bell's Palsy in Advanced Non-Small Cell Lung Carcinoma.
Indian J Otolaryngol Head Neck Surg
February 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Cheras, Malaysia.
Garcin syndrome is an exceptional clinical condition characterized by progressive multiple ipsilateral cranial nerve involvement which is caused by malignant osteoclastic lesion at skull base. We report a rare case of Garcin syndrome which was misdiagnosed as Bell's palsy. A 69-year-old lady, presented with generalized headache and right facial nerve palsy in which progressively worsened even after treatment with corticosteroid.
View Article and Find Full Text PDFA Mini-Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms.
Curr Pharm Des
March 2025
Pharmacy Department, Tishk International University, Erbil, Iraq.
Background: An essential component of cell development, proliferation, and survival is the transmembrane receptor known as the epidermal growth factor receptor (EGFR). Dysregulated EGFR signalling is an appealing pathway that has been linked to the genesis and progression of several cancer types. EGFR tyrosine kinase inhibitors (TKIs) are targeted drugs that show promise in the fight against cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.